Additional file 1: Figures S1 and S2. of Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial

Figure S1. The individual participant levels of iFGF23 (pg/mL), cFGF23 (RU/mL) and phosphate (mmol/L) over the course of the study for participants randomized to iron sucrose (left panels) and ferric carboxymaltose (right panels). Figure S2. The individual participant levels of serum hepcidin (ng/mL) ferritin (Οg/L), and haemoglobin (g/L) over the course of the study for participants randomized to iron sucrose (left panels) or ferric carboxymaltose (right panels). (PDF 670 kb

Additional file 2: Table S1. of Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial

Median (IQR) levels of iFGF23, cFGF23, ferritin, hepcidin and phosphate at Day 0, 2, 7, 21 and Day 42, by randomized treatment group. (PDF 93 kb

Additional file 1: Table S1. of Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial

Baseline characteristics (ITT population). (DOCX 12 kb

Additional file 2: Table S2. of Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial

Mean (SD) change in estimated GFR (eGFR) from baseline to month 12 for subpopulations of patients with eGFR values both time points. (DOCX 12 kb